Yang Cao - 19 Sep 2022 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
Chief Regulatory Officer
Signature
/s/ Yang Cao by Dale A. Sander as Attorney-in-Fact
Issuer symbol
HUMA
Transactions as of
19 Sep 2022
Net transactions value
$0
Form type
4
Filing time
20 Sep 2022, 16:09:47 UTC
Next filing
12 Dec 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Award $0 +145,000 $0.000000 145,000 19 Sep 2022 Common Stock 145,000 $3.73 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The first 25% of the option becomes exercisable on September 19, 2023, after which 1/48 of the option will become exercisable on the 19th of each month through September 19, 2026.